The best overall treatment strategy for patients with acute promyelocytic leukaemia (APL) in relapse with chemotherapy, bone marrow transplantation (BMT) or arsenic trioxide (As 2 O 3 ) based therapy remains undefined.
Introduction
Acute promyelocytic leukaemia (APL) is characterised by t(15; 17)(q22; q21), which results in PML/RARA gene fusion. It is highly sensitive to all-trans retinoic-acid (ATRA), which acts as a differentiation agent [1] , and arsenic trioxide (As 2 O 3 ), which induces both differentiation and apoptosis [2] . Although APL blasts are very sensitive to chemotherapy, particularly anthracyclines [3] , induction chemotherapy is associated with early death due mainly to haemorrhagic complications [4] . With the use of ATRA combined with chemotherapy, haemorrhagic complications can largely be avoided. However, up to 20% of patients still relapse, despite the use of chemotherapy and ATRA as consolidation and maintenance treatment [5] .
In relapsed APL, the best treatment strategy remains contentious. Some patients are still responsive to ATRA and chemotherapy. Allogeneic bone marrow transplantation (BMT) may give lasting remissions, but the patient selection and timing for BMT are unresolved issues. Clinical and laboratory evidence indicates that As 2 O 3 is a highly effective treatment for relapsed APL. However, the role of As 2 O 3 , in comparison with further chemotherapy or allogeneic BMT, has not hitherto been formally evaluated.
In this report, we studied the treatment results of newly diagnosed and relapsed cases of APL over a 10-year period, with a specific focus on evaluating the relative merits of chemotherapy, allogeneic BMT and As 2 O 3 in the treatment of relapses.
Materials and methods

Patients
All patients with APL treated between 1991 and 2001 were included in the analysis. They were treated in four tertiary referral centres (Queen Mary Hospital, Queen Elizabeth Hospital, Tuen Mun Hospital, Pamela Youde Nethersole Hospital) that served over 70% of leukaemia patients in Hong Kong during that time period. The diagnosis of APL was based on marrow morphology, and was confirmed by cytogenetic and/or molecular investigations [6] . 
Treatment of newly diagnosed APL
Treatment of relapsed APL
All relapses were diagnosed by marrow biopsy and confirmed cytogenetically or molecularly (Table 1) . From 1991 to 1997, chemotherapy and ATRA were used for induction of second complete remission (CR2) (n = 33). Patients reaching CR2 and with a suitable marrow donor (n = 14) proceeded to allogeneic BMT, while the others (n = 19) received consolidation with conventional chemotherapy. After 1997, As 2 O 3 (10 mg daily until remission) and idarurbicin (72 mg/m 2 in nine divided doses over 3 months) were used in all relapsed cases (n = 21), as previously reported [7] . Patients who relapsed again after As 2 O 3 /idarubicin treatment (n = 8) were further treated with As 2 O 3 (10 mg/m 2 /day) and ATRA (45 mg/m 2 /day) until CR3, followed by further consolidation with As 2 O 3 plus ATRA, each given for 14 days every 4-6 weeks for six courses, as reported previously [8] .
Allogeneic BMT
From 1991 to 1997, all relapsed patients reaching CR2 and with a human leukocyte antigen (HLA)-identical donor (n = 14; 13 from siblings and one from a matched-unrelated donor) were considered suitable for allogeneic BMT (Table 2 ). There were no exclusion criteria. Conditioning regimen comprised: busulphan (16 mg/kg) and cyclophosphamide (120 mg/kg) in four cases; and busulphan (7 mg/kg), cyclophosphamide (50 mg/kg) and total body irradiation (TBI; 12 Gy) in 10 cases. Melphalan (100 mg/m 2 ) and TBI (12 Gy) was used for the second BMT in one patient (case 1; Table 2 ). Cyclosporine and methotrexate was used in all cases for graft-versus-host disease (GvHD) prophylaxis.
Statistical analysis
Data were censored on the last day of 2001. For the whole group, actuarial survival was calculated by Kaplan-Meier analysis. Patients with or without Table 2 . Outcome of 14 acute promyelocytic leukaemia patients treated with allogeneic bone marrow transplantation (BMT) M, male; F, female; time, time from initial diagnosis to BMT in months; R, relapse; CR, complete remission; Bu, busulphan; Cy, cyclophosphamide; TBI, total body irradiation; Plt >25, days to platelet count >25 × 10 9 /l; ANC >1, days to absolute neutrophil count >1 × 10 9 /l; GvHD, acute graft-versushost disease (grades 0-4); OS, overall survival in months; DFS, disease-free survival in months; +, survivor; cGvHD, chronic graft-versus-host disease; AVN, avascular necrosis of hip. a One month of marrow aplasia with spontaneous recovery due to idiosyncratic hypersensitivity to azathioprine for GvHD. was calculated from the day of diagnosis to the day of death or censorship. Disease-free survival (DFS) was calculated from the day of diagnosis to the day of confirmed marrow relapse. For salvage cases, analysis of OS was from the day of relapse to the day of death or censorship. The log-rank model was used to analyse differences in OS for the three different treatment methods for relapses (chemotherapy, BMT, As 2 O 3 -based treatment).
Results
Treatment outcome of newly diagnosed APL
A total of 153 patients were diagnosed with APL within the study period ( Figure 1) . Complete data for analysis were available in 143 patients. A total of 30 patients died before or during induction chemotherapy. CR1 was achieved in 113 cases. Relapses occurred in 54 patients, at a median of 13 months (range 5-96 months). Late relapses, defined as relapses occurring 2 years after CR1, occurred in 10 cases. The 5-year actuarial DFS from CR1 was 42%. This did not differ significantly for patients with (n = 59) and without (n = 54) maintenance therapy (P = 0.087), owing to the occurrence of more late relapses in the latter group (Figure 2 ).
Treatment outcome of APL in first relapse
The results of different treatment groups (chemotherapy alone, n = 19; chemotherapy followed by allogeneic BMT, n = 14; As 2 O 3 followed by chemotherapy, n = 21) are shown in Table 1 and Figure 3 . Ten patients treated with chemotherapy and five patients receiving BMT died from early treatment-related complications. Two patients receiving BMT died from late complications (hepatitis B virus-related liver failure and bronchiolitis obliterans) ( Table 2) . Durable CR2 was achieved in 30 cases.
Treatment of APL in second or more advanced relapses
There were 11 further relapses at a median of 11 months (range 8-48 months) ( Table 1 ). Both patients in the chemotherapy group received further chemotherapy, and died from treatment-related complications. The only patient who relapsed again in the BMT group received a second allogeneic BMT from an HLA-identical sibling, and has remained in CR3. Two patients in the As 2 O 3 group died before further treatment could be given. Six patients achieved and have remained in remission, with combined As 2 O 3 plus ATRA therapy.
Statistical analysis
The 2-year actuarial OS from R1 leveled off at 23% for the chemotherapy group, 43% for the BMT group and 82% for the As 2 O 3 group ( Figure 3) . As a result of efficient salvage of advanced relapses, the 5-year actuarial OS from CR1, at 68%, was much better than the DFS. 
Discussion
With ATRA and chemotherapy as the induction regimen, the CR rate of 79% observed in this study is comparable to those of 72% and 96% reported previously [9] . However, our 5-year DFS, at 42%, was apparently inferior to the reported 3-year DFS of 86% to 90% in other series [10] . A number of reasons might account for this. One of the four centres in our study has not used maintenance therapy, which has been shown to be of beneficial effect in reducing relapses [11] . Furthermore, chemotherapy tolerance appears to be poor in Chinese people, and full-dose mercaptopurine maintenance was not achievable in most cases [12] . In relapsed APL, allogeneic BMT, chemotherapy and As 2 O 3 are all useful treatment modalities, but the best choice and timing of treatment is as yet undefined [13] . Reported data on the use of ATRA plus chemotherapy for relapsed APL showed that only 29-35% of patients could be induced into durable remission [14, 15] . Allogeneic BMT for relapsed patients who achieved a second remission after ATRA plus chemotherapy also gave poor results. In one study, the leukaemia-free survival (LFS) was 22%, relapse rate (RR) was 54%, and the treatment-related mortality (TRM) was 40% [16] . In another study, only two of 11 APL patients in second remission survived the transplantation [17] . Data published by the European Blood and Marrow Transplantation (EBMT) Group showed that in 127 relapsed APL patients who received allogeneic BMT, the LFS was 53-61%, the RR was 10-22% and the TRM was 32-34% [18] . The data from the EBMT appeared to be slightly better than the former two studies, which could be related to different patient selection. However, these studies all showed that allogeneic BMT in APL patients in second remission was associated with a high TRM and an overall unsatisfactory outcome. As for As 2 O 3 , although a high remission rate can be achieved, the long-term follow-up results are less well defined. In two series comprising 87 relapsed cases, the 18-and 24-month LFS was 56% and 42%, respectively [19, 20] .
In comparison with the studies of relapsed APL described above, our data offer a few advantages. This study involved a consecutive series, so that bias related to patient selection for various treatment options was diminished. This was particularly important for BMT, where patient selection could often affect the treatment outcome. Furthermore, the treatment and supportive care were similar. Our results might therefore give a better perspective on the relative merits of the different treatment options in relapsed APL.
We showed that with a follow-up of 3 years, treatment results for BMT were comparable to chemotherapy, but inferior to arsenic-based treatment for relapsed APL. The lower relapse rate with BMT was offset by the high early TRM, a phenomenon also observed in other studies [16] [17] [18] . Although few late relapses occurred after BMT, the survival curve remained unstable owing to late deaths from GvHD and organ toxicity. Furthermore, survivors after BMT might still suffer from the permanent side effects of immunosuppression, exposure to alkylating agents, infertility, premature menopause and increased risks of secondary malignancies. In contrast, As 2 O 3 -based therapy was associated with minimal toxicity or mortality. Although As 2 O 3 -induced second remissions were apparently associated with more subsequent relapses, long-term remission after combination therapy with As 2 O 3 and ATRA might still be achieved in these patients [8] . Furthermore, the lack of organ damage meant that further relapses might still be salvaged by allogeneic BMT, although this was not required in any of our cases. Our results therefore suggest that As 2 O 3 -based therapy may be the treatment of choice for APL in first or more advanced relapses. For this reason, we have not performed BMT in any APL patients after 1997.
In conclusion, the availability of effective first-line and salvage therapy means that APL patients in any stage of their illness should be treated with curative intent, even when they have late advanced diseases [13] . As 2 O 3 appears to be the best option for relapsed cases. The high efficacy of As 2 O 3 in inducing second remissions means that optimal consolidation and maintenance of remission are key factors that will improve the cure rate. For allogeneic BMT to be offered as a consolidation, TRM must be improved. On the other hand, APL in advanced and repeated relapse appears to continue to respond to As 2 O 3 treatment, which is associated with minimal side effects. Among these options, our data with short-term follow-up seemed to favour the use of repeated courses of As 2 O 3 . However, prospective clinical trials are needed to fully resolve the issue of As 2 O 3 as compared with allogeneic BMT as the optimal treatment for relapsed APL.
